| Date | Title | | | Jul 28, 2010 | Dyax Corp. Announces Second Quarter 2010 Financial Results| Quarter Highlighted By 266% Increase in KALBITOR(R) (ecallantide) Patients-
CAMBRIDGE, Mass., Jul 28, 2010 (BUSINESS WIRE) -- Dyax Corp. (NASDAQ: DYAX) today announced financial results for the second quarter ended June 30, 2010. Dyax will host a webcast and conference call at 10 a.m. (ET) this morning to review the financial results and corporate progress for the quarter.
Patients currently in KALBITOR AccessSM program expanded to 264
HAE patients with KALBITOR(R) (ecallantide) at th... |
|  | | Jul 21, 2010 | Dyax Corp. to Host Second Quarter 2010 Earnings Call and Webcast| CAMBRIDGE, Mass., Jul 21, 2010 (BUSINESS WIRE) -- Dyax Corp. (NASDAQ:DYAX) will host a webcast and conference call, including an open question and answer session, Wednesday, July 28, 2010, to discuss its financial results and company progress for the second quarter ended June 30, 2010.
Date:
Wednesday, July 28, 2010
Time:
10:00 a.m. ET
Telephone Access:
Domestic callers, dial 800-561-2601
International callers, dial 617-... |
| | | Jul 19, 2010 | Dyax Features Comprehensive Financial Assistance Program On Enhanced Product Website for KALBITOR(R) (ecallantide)| CAMBRIDGE, Mass., Jul 19, 2010 (BUSINESS WIRE) --
Dyax Corp. (NASDAQ:DYAX) today announced that it has launched its newly enhanced product website, http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.KALBITOR.com&esheet=6363207&lan=en-US&anchor=www.KALBITOR.com&index=3&md5=daf9eacd6f4f7439a22b3620141c703c, featuring its comprehensive financial assistance program. KALBITOR(R) (ecallantide) is approved for the treatment of acute attacks of hereditary angioe... |
| | | Jul 6, 2010 | Dyax Announces Marketing Authorization Application for DX-88 (ecallantide) Validated by European Medicines Agency| CAMBRIDGE, Mass., Jul 06, 2010 (BUSINESS WIRE) --
Dyax Corp. (NASDAQ: DYAX) announced today that the European Medicines Agency (EMA) has completed its validation process for the Marketing Authorization Application (MAA) for potential approval to market DX-88 (ecallantide) in the European Union (EU). The completion of this validation process signifies that the formal scientific review of the MAA has begun. DX-88 (ecallantide) has been approved by the U.S. Food and Drug Administration (FDA) and i... |
| | | Jun 21, 2010 | Dyax and Sigma-Tau Announce Partnership to Develop and CommercializeSubcutaneous DX-88 (ecallantide) for Hereditary Angioedema and Other Indications in Europe, North Africa, Middle East and Russia| Dyax Receives $5M Upfront Payment
CAMBRIDGE, Mass., Jun 21, 2010 (BUSINESS WIRE) --Dyax Corp. (NASDAQ: DYAX) and Defiante Farmaceutica S.A., a subsidiary of the pharmaceutical company Sigma-Tau SpA (Sigma-Tau), announced today a strategic partnership to develop and commercialize subcutaneous DX-88 (ecallantide) for the treatment of hereditary angioedema (HAE) and other therapeutic indications throughout Europe, North Africa, Middle East and Russia. Dyax retains its rights to subcutaneous DX-8... |
| | | Jun 7, 2010 | Dyax Announces Publication of KALBITOR(R) (ecallantide) EDEMA4(R) Trial Results in the Annals of Allergy, Asthma, and Immunology| Benefit of KALBITOR for Acute HAE Attack Symptoms Demonstrated at Four Hours Post-Treatment
CAMBRIDGE, Mass., Jun 07, 2010 (BUSINESS WIRE) --Dyax Corp. (NASDAQ: DYAX) announced today the publication of results from its second Phase 3, placebo-controlled trial, known as EDEMA4(R), evaluating KALBITOR (ecallantide) for the treatment of acute attacks of hereditary angioedema (HAE). The results, published in the June 2010 issue of the Annals of Allergy, Asthma, and Immunology, indicate that KALBIT... |
| | | Jun 2, 2010 | Dyax Corp. to Present at June 2010 Investor Conferences| CAMBRIDGE, Mass., Jun 02, 2010 (BUSINESS WIRE) --Dyax Corp. (NASDAQ:DYAX), a developer of novel biotherapeutics for unmet medical needs, announced today that company management of Dyax will present at three investor conferences in June:
George Migausky, Executive Vice President and Chief Financial Officer, will present on Wednesday, June 9th at 9:20 AM (ET) at the 9th Annual Needham Healthcare Conference being held June 9-10th at The New York Palace Hotel in New York City.
Gustav Christe... |
| | | May 10, 2010 | Dyax Corp. to Present at the Rodman & Renshaw Annual Global Investment Conference| CAMBRIDGE, Mass., May 10, 2010 (BUSINESS WIRE) --Dyax Corp. (NASDAQ:DYAX), a developer of novel biotherapeutics for unmet medical needs, announced today that Gustav A. Christensen, President and Chief Executive Officer of Dyax, will present at the Rodman & Renshaw 6th Annual Global Investment Conference, being held May 16-18th at the Grosvenor House Hotel in London, UK. Mr. Christensen will present a corporate progress report, including an update on the Company's commercial activities for KA... |
| | | Apr 28, 2010 | Dyax Corp. Announces First Quarter 2010 Financial Results| CAMBRIDGE, Mass., Apr 28, 2010 (BUSINESS WIRE) --Dyax Corp. (NASDAQ: DYAX) today announced financial results for the first quarter ended March 31, 2010. Dyax will host a webcast and conference call at 10 a.m. (ET) this morning to review the financial results and corporate progress for the quarter.
Financial Results
Total revenues for the first quarter ended March 31, 2010 increased to $20.0 million, as compared to $6.0 million for the same quarter in 2009. The 2010 increase was due to $1.2 mi... |
| | | Apr 21, 2010 | Dyax Corp. to Host First Quarter 2010 Earnings Call and Webcast| CAMBRIDGE, Mass., Apr 21, 2010 (BUSINESS WIRE) --Dyax Corp. (NASDAQ:DYAX) will host a webcast and conference call, including an open question and answer session, Wednesday, April 28, 2010, to discuss its financial results and company progress for the first quarter ended March 31, 2010.
Date:
Wednesday, April 28, 2010
Time:
10:00 a.m. ET
Telephone Access:
Domestic callers, dial 800-659-2037
International callers, dial 617-614-2713
... |
| | | Apr 20, 2010 | Dyax Corp. Sells Rights to Xyntha(R) Royalty Stream to Paul Capital Healthcare for up to $12 Million| CAMBRIDGE, Mass., Apr 20, 2010 (BUSINESS WIRE) --Dyax Corp. (NASDAQ: DYAX) announced today that it has sold its rights to royalties and other payments related to the commercialization of Xyntha(R) by Pfizer, Inc., a licensee under the Company's phage display Licensing and Funded Research Program (LFRP), to an investment fund managed by Paul Capital Healthcare. Under the terms of this sale, Dyax received an upfront cash payment of $10 million and will be eligible to receive milestone payments tot... |
| | | Apr 5, 2010 | Dyax Announces Underwriter's Exercise of Over-allotment Option| CAMBRIDGE, Mass., Apr 05, 2010 (BUSINESS WIRE) --Dyax Corp. (NASDAQ: DYAX) announced today that Jefferies & Company, Inc. exercised in full its over-allotment option to purchase an additional 2,550,000 shares of the Company's common stock at a public offering price of $3.25 per share. The over-allotment option was granted to the underwriters by Dyax in connection with its recent offering of common stock. The exercise of the option brings the aggregate net proceeds from the offering to approx... |
| | | Apr 5, 2010 | Dyax Corp. to Present at the 2010 Future Leaders in the Biotech Industry Conference| CAMBRIDGE, Mass., Apr 05, 2010 (BUSINESS WIRE) --Dyax Corp. (NASDAQ: DYAX), a developer of novel biotherapeutics for unmet medical needs, announced today that George Migausky, Executive Vice President and Chief Financial Officer of Dyax, will present at the BioCentury and ThomsonReuters 17th Annual Future Leaders in the Biotech Industry Conference, being held April 8th at the Millennium Broadway Hotel in New York City. Mr. Migausky will present a corporate progress report, including an update on... |
| | | Apr 5, 2010 | First-Ever Published Study Underscores Significant Economic Burden of Hereditary Angioedema on Patients, Families and the Healthcare System| CAMBRIDGE, Mass., Apr 05, 2010 (BUSINESS WIRE) --Dyax Corp. (NASDAQ: DYAX) announced the publication of a first-ever comprehensive examination of the economic burden associated with the treatment of acute attacks and chronic management of hereditary angioedema (HAE). The results, published today in the Annals of Allergy, Asthma, and Immunology, bring to light the substantial direct and indirect medical costs of the disease on patients, payers and society. The economic study is one component of a... |
| | | Mar 25, 2010 | Dyax Announces Pricing of Public Offering of Common Stock| CAMBRIDGE, Mass., Mar 25, 2010 (BUSINESS WIRE) -- Dyax Corp. (NASDAQ: DYAX) today announced the pricing of an underwritten public offering of 17,000,000 shares of its common stock at a price to the public of $3.25 per share. The gross proceeds from the sale of shares, after underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $51.8 million. The offering is expected to close on or about March 30, 2010, subject to customary closing conditions.
... |
| | | Mar 24, 2010 | Dyax Announces Proposed Public Offering of Common Stock| CAMBRIDGE, Mass., Mar 24, 2010 (BUSINESS WIRE) -- Dyax Corp. (NASDAQ: DYAX) today announced that it is offering to sell shares of its common stock in an underwritten public offering. Jefferies & Company, Inc. is acting as the sole book-running manager of the offering with Needham & Company, LLC acting as the co-lead manager. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of t... |
| | | Mar 2, 2010 | KALBITOR(R) (ecallantide) Data Presented at American Academy of Allergy, Asthma and Immunology Annual Meeting| Results of KALBITOR Efficacy for HAE Acute Attacks by Attack Location
CAMBRIDGE, Mass., Mar 02, 2010 (BUSINESS WIRE) -- Datademonstrating the effectiveness of KALBITOR (ecallantide) to treat hereditary angioedema (HAE) acute attacks by primary attack location were provided in an oral presentation yesterday at the American Academy of Allergy, Asthma and Immunology (AAAAI) 2010 Annual Meeting in New Orleans. KALBITOR, discovered and developed by Dyax Corp. (NASDAQ:DYAX), was approved by the U.S.... |
| | | Feb 24, 2010 | Dyax Corp. to Present at the Cowen and Company Health Care Conference| CAMBRIDGE, Mass., Feb 24, 2010 (BUSINESS WIRE) -- Dyax Corp. (NASDAQ:DYAX), a developer of novel biotherapeutics for unmet medical needs, announced today that Gustav A. Christensen, President and Chief Executive Officer of Dyax, will present at the Cowen and Company 30th Annual Health Care Conference, being held March 8-11th at the Marriott Copley Place in Boston, MA. Mr. Christensen will present a corporate progress report, including an update on the Company's commercial activities for KALBITOR... |
| | | Feb 17, 2010 | Dyax Corp. Announces Fourth Quarter and Year End 2009 Financial Results| CAMBRIDGE, Mass., Feb 17, 2010 (BUSINESS WIRE) -- Dyax Corp. (NASDAQ: DYAX) today announced financial results for the fourth quarter and year ended December 31, 2009. Dyax will host a webcast and conference call at 10 a.m. (ET) this morning to review the financial results and corporate progress for the quarter.
Financial Results
Total revenues for the fourth quarter ended December 31, 2009 were $6.3 million, as compared to $31.5 million for the comparable quarter in 2008. Revenues for the yea... |
| | | Feb 10, 2010 | Dyax Corp. to Host Fourth Quarter and Year End 2009 Earnings Call and Webcast| CAMBRIDGE, Mass., Feb 10, 2010 (BUSINESS WIRE) -- Dyax Corp. (NASDAQ:DYAX) will host a webcast and conference call, including an open question and answer session, Wednesday, February 17, 2010, to discuss its financial results and company progress for the fourth quarter and year ended December 31, 2009.
Date:
Wednesday, February 17, 2010
Time:
10:00 a.m. ET
Telephone Access:
Domestic callers, dial 866-804-6921
International callers, dial 857-350-1667
... |
| | | Feb 2, 2010 | KALBITOR(R) (ecallantide) Now Commercially Available| KALBITOR Orders Being Coordinated Through KALBITOR AccessSM --Call 1-888-452-5248 or Visit www.KALBITOR.com for Information CAMBRIDGE, Mass., Feb 02, 2010 (BUSINESS WIRE) -- Dyax Corp. (NASDAQ:DYAX) announced today that KALBITOR(R) (ecallantide) for the treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older is now commercially available in the United States.
HAE is a rare, genetic disorder characterized by severe, debilitating and often painful swelling... |
| | | Feb 1, 2010 | Dyax Corp. to Present at the BIO CEO & Investor Conference| CAMBRIDGE, Mass., Feb 01, 2010 (BUSINESS WIRE) -- Dyax Corp. (NASDAQ:DYAX), a developer of novel biotherapeutics for unmet medical needs, announced today that Gustav A Christensen, President and Chief Executive Officer of Dyax, will present at the 12th Annual BIO CEO & Investor Conference, being held February 8-9th at The Waldorf-Astoria Hotel in New York, NY. Mr. Christensen will present a corporate progress report, including an update on the Company's commercial activities for KALBITOR(R) ... |
| | | Jan 14, 2010 | Dyax Launches HAE Hope, A New Online Resource for Patients with Hereditary Angioedema| Website Offers Tools for Recognizing Attack Triggers and Managing the DiseaseCAMBRIDGE, Mass., Jan 14, 2010 (BUSINESS WIRE) -- A new, online resource is now available for patients with hereditary angioedema (HAE), their caregivers and physicians. The website, www.HAEHope.com, launched today by Dyax Corp. (NASDAQ: DYAX), offers resources to help patients and their families better understand and manage HAE, a rare, genetic disease characterized by episodes of severe and painful swelling.
A numbe... |
| |
|
